Kolexia
Morvan Francois
Oncologie médicale
Hôpital René Dubos
Pontoise, France
45 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs du côlon Carcinome épidermoïde Carcinome épidermoïde de la tête et du cou Complications tumorales de la grossesse Carcinomes Tumeurs colorectales Fragilité {{person.topmesh10.name}}

Industries

A+A
24 collaboration(s)
Dernière en 2023
AstraZeneca
14 collaboration(s)
Dernière en 2023
B3TSI
4 collaboration(s)
Dernière en 2023
Lilly
4 collaboration(s)
Dernière en 2023

Dernières activités

Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   15 novembre 2023
Abstract P1-18-16: First line aromatase inhibitor (AI) + palbociclib with randomized switch to fulvestrant + palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Global safety results of PADA-1, a UCBG-GINECO phase III trial
2021 San Antonio Breast Cancer Symposium   15 février 2022
Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial
2021 San Antonio Breast Cancer Symposium   15 février 2022
Predicting Chemotherapy Toxicity and Death in Older Adults with Colon Cancer: Results of MOST Study.
The oncologist   06 août 2019
Predicting chemotherapy toxicity and death in older adults with colon cancer: Results of MOST (Massilia Oncologic Senior Tests) study.
2018 ASCO Annual Meeting I   01 juin 2018
5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study.
European journal of cancer (Oxford, England : 1990)   03 avril 2018
Induction TPF followed by chemoradiation or radiotherapy-cetuximab in nonresectable advanced head and neck squamous cell carcinoma: A retrospective study in 164 patients.
2012 ASCO Annual Meeting I   20 mai 2012
{{person.lastact8.name}}
{{person.lastact8.jour}}   {{person.lastact8.date}}
{{person.lastact9.name}}
{{person.lastact9.jour}}   {{person.lastact9.date}}
{{person.lastact10.name}}
{{person.lastact10.jour}}   {{person.lastact10.date}}